Literature DB >> 9390841

Episodic ataxia type 1 and 2 (familial periodic ataxia/vertigo).

T Brandt1, M Strupp.   

Abstract

Episodic ataxia (EA) is a rare, disabling condition of autosomal dominant inheritance, but it is not a distinct clinical entity. Synonyms are familial periodic ataxia or hereditary paroxysmal cerebellar ataxia. Family members have a similar clinical syndrome; however, the syndrome varies considerably from family to family. At least two groups of disorders have been separated clinically: (1) episodic ataxia type 1 (EA-1), which manifests without vertigo and is associated with 'interictal' myokymia, and (2) episodic ataxia type 2 (EA-2), which often manifests with vertigo and is associated with 'interictal' nystagmus. EA-1 and EA-2 have been identified as channelopathies. EA-1 is due to different heterozygous missense point mutations in a voltage-gated (delayed rectifier) potassium channel gene (KCNA1/Kv1.1) on chromosome 12p13, whereas EA-2 is caused by mutations of the cerebral P/Q-type calcium channel alpha 1 subunit gene CACNL1A4 localized on chromosome 19p, which is highly expressed in the cerebellum. The diagnosis of EA-1 and EA-2 is important, since they can be easily treated and are often mislabeled. As effective as acetazolamide is in preventing attacks, prospective studies still have to prove whether it can prevent progressive ataxia in EA-2 or even improve chronic cerebellar deficits.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390841     DOI: 10.1159/000259262

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  9 in total

1.  Brownian dynamics simulations of the recognition of the scorpion toxin maurotoxin with the voltage-gated potassium ion channels.

Authors:  Wei Fu; Meng Cui; James M Briggs; Xiaoqin Huang; Bing Xiong; Yingmin Zhang; Xiaomin Luo; Jianhua Shen; Ruyun Ji; Hualiang Jiang; Kaixian Chen
Journal:  Biophys J       Date:  2002-11       Impact factor: 4.033

Review 2.  Potassium channels: a review of broadening therapeutic possibilities for neurological diseases.

Authors:  Snezana Maljevic; Holger Lerche
Journal:  J Neurol       Date:  2012-11-11       Impact factor: 4.849

3. 

Authors:  F Schmäl; W Stoll
Journal:  HNO       Date:  2003-10       Impact factor: 1.284

Review 4.  Migraine genetics: an update.

Authors:  J Haan; E E Kors; Kaate R J Vanmolkot; Arn M J M van den Maagdenberg; Rune R Frants; M D Ferrari
Journal:  Curr Pain Headache Rep       Date:  2005-06

Review 5.  Migraine genetics.

Authors:  Esther Kors; Joost Haan; Michel Ferrari
Journal:  Curr Pain Headache Rep       Date:  2003-06

Review 6.  Episodic ataxia type 2.

Authors:  Michael Strupp; Andreas Zwergal; Thomas Brandt
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

7.  A novel locus for adolescent idiopathic scoliosis on chromosome 12p.

Authors:  Cathleen L Raggio; Philip F Giampietro; Seth Dobrin; Chengfeng Zhao; Donna Dorshorst; Nader Ghebranious; James L Weber; Robert D Blank
Journal:  J Orthop Res       Date:  2009-10       Impact factor: 3.494

8.  A novel locus for episodic ataxia:UBR4 the likely candidate.

Authors:  Judith Conroy; Paul McGettigan; Raymond Murphy; David Webb; Sinéad M Murphy; Blathnaid McCoy; Christine Albertyn; Dara McCreary; Cara McDonagh; Orla Walsh; Sallyann Lynch; Sean Ennis
Journal:  Eur J Hum Genet       Date:  2013-08-28       Impact factor: 4.246

9.  Vertigo and vestibular abnormalities in spinocerebellar ataxia type 6.

Authors:  Patrick Yu-Wai-Man; Grainne Gorman; David E Bateman; R John Leigh; Patrick F Chinnery
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.